Skip to main content
ADIM logo

ADIM — Investor Relations & Filings

Ticker · 4142 ISIN · TW0004142005 LEI · 549300M5TV8YGVXU1827 TW Manufacturing
Open in API
Filings indexed 1,804 across all filing types
Latest filing 2017-12-08 Regulatory Filings
Country TW Taiwan
Listing TW 4142

About ADIM

http://www.adimmune.com.tw/

ADIMMUNE CORPORATION, established in 1965, specializes in the research, development, and large-scale manufacturing of human vaccines and biologics. The company is a primary supplier of seasonal influenza and tetanus vaccines, maintaining production facilities that adhere to PIC/S GMP, US FDA, and EU standards. Its operations encompass the full product lifecycle, from initial R&D to commercial distribution. In addition to its proprietary vaccine portfolio, the company provides Contract Development and Manufacturing Organization (CDMO) services, supporting collaborative development and global supply chains. Recognized for its technical expertise in viral and bacterial vaccine production, the organization focuses on delivering high-quality immunization solutions to international markets while leveraging its history as a pioneering vaccine laboratory.

Recent filings

Filing Released Lang Actions
106年11月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, providing information about loan balances and endorsement guarantees for the current and previous months. It contains no detailed financial statements, management discussion, or regulatory certifications. The content is concise and factual, typical of a regulatory announcement or compliance disclosure rather than a full report or detailed filing. Given the short length (616 characters) and the nature of the data, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-12-08 Chinese
106年11月營業收入
Interim / Quarterly Report Classification · 90% confidence The document is a summarized revenue report for a specific month and year (民國106年11月, which corresponds to November 2017) provided by a listed company (國光生). It contains monthly and cumulative revenue figures, percentage changes, and explanations for revenue changes. The document is very short (787 characters) and primarily presents financial data for a short period (monthly and year-to-date). It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR), but it does provide substantive financial data and explanations for changes in revenue. This fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains actual financial data and analysis, not just an announcement or summary. Therefore, the appropriate classification is IR with high confidence. 9M 2017
2017-12-08 Chinese
106年第3季財務報告書 — 201704_4142_AI3.pdf
Audit Report / Information Classification · 95% confidence The document is titled as a financial report for the years 2017 and 2016 (民國106年度及105年度) for 國光生物科技股份有限公司, including detailed financial statements such as individual balance sheets, comprehensive income statements, changes in equity, cash flow statements, and notes to the financial statements. It also contains an auditor's report (會計師查核報告) with audit opinions, basis of audit, key audit matters, and responsibilities of management and auditors. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of detailed financial data, audit opinions, and comprehensive notes confirms this is a full annual financial report with audit information. Therefore, the document fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) because it is specifically an individual financial report with auditor's report, not a full annual report covering all company activities. The document is not a short announcement or certification, so it is not RPA or RNS. Hence, the best classification is AR with high confidence. FY 2017
2017-11-14 Chinese
106年第3季財務報告書 — 201704_4142_AI1.pdf
Regulatory Filings
2017-11-14 Chinese
106年第3季財務報告書 — 201703_4142_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "合併財務報告暨會計師核閱報告" which translates to "Consolidated Financial Report and Accountant's Review Report" for the third quarter of years 106 and 105 (Taiwanese calendar years, corresponding to 2017 and 2016). It includes detailed financial statements such as consolidated balance sheets, income statements, statements of changes in equity, and cash flow statements. It also contains an accountant's review report (核閱報告) rather than a full audit opinion, indicating it is a reviewed interim financial report rather than a full annual audit report. The presence of quarterly dates and the nature of the report (reviewed financials for a quarter) aligns with an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2017
2017-11-14 Chinese
106年第3季財務報告書 — 201702_4142_AI1.pdf
Regulatory Filings
2017-11-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.